Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

477.9 (USD) • At close September 19, 2024
Bedrijfsnaam Vertex Pharmaceuticals Incorporated
Symbool VRTX
Munteenheid USD
Prijs 477.9
Beurswaarde 123,346,945,322
Dividendpercentage 0%
52-weken bereik 341.85 - 510.64
Industrie Biotechnology
Sector Healthcare
CEO Dr. Reshma Kewalramani FASN, M.D.
Website https://www.vrtx.com

An error occurred while fetching data.

Over Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF

Vergelijkbare Aandelen

Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGN

1,150.19 USD

Intuitive Surgical, Inc. logo

Intuitive Surgical, Inc.

ISRG

490.01 USD

Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILD

83.9 USD

Moderna, Inc. logo

Moderna, Inc.

MRNA

68.02 USD

Illumina, Inc. logo

Illumina, Inc.

ILMN

134.39 USD

Walgreens Boots Alliance, Inc. logo

Walgreens Boots Alliance, Inc.

WBA

8.98 USD

IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc.

IDXX

517.06 USD

Biogen Inc. logo

Biogen Inc.

BIIB

201.44 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)